Stem cell factor (SCF) and its receptor c-Kit have been implicated in tissue remodelling and fibrosis. Alveolar fibroblasts from patients with diffuse interstitial fibrosis secrete more SCF. However, its precise role remains unclear. In this study the potential role of the SCF-c-Kit axis in pulmonary fibrosis was examined. Fibrosis was induced by intratracheal instillation of bleomycin (BLM), which caused increased SCF levels in plasma, bronchoalveolar lavage fluid (BALF) and lung tissue, as well as increased expression by lung fibroblasts. These changes were accompanied by increased numbers of bone marrow-derived c-Kit + cells in the lung, with corresponding depletion in bone marrow. Both recombinant SCF and lung extracts from BLM-treated animals induced bone-marrow cell migration, which was blocked by c-Kit inhibitor. The migrated cells promoted myofibroblast differentiation when co-cultured with fibroblasts, suggesting a paracrine pathogenic role. Interestingly, lung fibroblast cultures contained a subpopulation of cells that expressed functionally active c-Kit, which were significantly greater and more responsive to SCF induction when isolated from fibrotic lungs, including those from patients with idiopathic pulmonary fibrosis (IPF). This c-Kit + subpopulation was αSMA-negative and expressed lower levels of collagen I but significantly higher levels of TGFβ than c-Kit-negative cells. SCF deficiency achieved by intratracheal treatment with neutralizing anti-SCF antibody or by use of Kitl Sl /Kitl Sl-d mutant mice in vivo resulted in significant reduction in pulmonary fibrosis. Taken together, the SCF-c-Kit pathway was activated in BLM-injured lung and might play a direct role in pulmonary fibrosis by the recruitment of bone marrow progenitor cells capable of promoting lung myofibroblast differentiation.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive, usually fatal lung disease of unknown aetiology, characterized by the accumulation of fibroblasts/myofibroblasts with aberrant remodelling of the lung parenchyma. Fibroblasts represent the key source of interstitial collagens; however, the mechanisms underlying the emergence of these cells and their differentiation into myofibroblasts are not fully understood. There is mounting evidence that bone marrow (BM)-derived cells are chemotactically recruited to the lung in response to signals released in reaction to lung injury and may play important roles in the process of repair and fibrosis [1] . Some of these cells have been implicated as extrapulmonary sources of fibroblasts or fibroblast-like cells capable of elaborating factors to promote myofibroblast differentiation from endogenous lung fibroblasts. Hence, improved understanding of the signals responsible for the recruitment and activation of bone marrow derived cells would be of great benefit to current understanding of the fibrotic process.
Stem cell factor (SCF) is expressed as soluble or membrane-bound forms and promotes survival, proliferation, mobilization from the bone marrow and adhesion of haematopoietic stem cells and other progenitor cells through binding with its cognate receptor, c-Kit [2] [3] [4] [5] [6] . Recent studies of multiple tissues, including the liver, kidney, heart and brain, indicate that the SCF-cKit axis is important for tissue remodelling and fibrosis [7] [8] [9] [10] [11] [12] . In the lung their potential importance in IPF is suggested by a study showing that alveolar fibroblasts from patients with diffuse interstitial fibrosis secrete more SCF than cells from sarcoidosis patients [13] . In a 206 L Ding et al murine model of asthma, neutralization of SCF in vivo significantly attenuated airway remodelling and collagen deposition, and strongly suppressed the recruitment of BM-derived collagen I-expressing cells to the lung [14] . This may be dependent on fibrogenic factor production by SCF-responsive cells, such as eosinophils and mast cells, but a direct role for SCF-c-Kit in recruitment and activation of BM-derived fibroblastlike cells has not been excluded. These findings provide a compelling argument for further examination of the essential role of the SCF-c-Kit axis in pulmonary fibrosis.
In this study, these findings were extended to lung parenchymal fibrosis, using the bleomycin (BLM)-induced model to provide evidence that the SCF-c-Kit pathway was activated and might play a direct role in pulmonary fibrosis by the recruitment of c-Kit + bone marrow cells to sites of lung. The essential role of this pathway was demonstrated by reduced fibrosis in mice with SCF deficiency, due either to neutralizing antibody treatment or a genetic defect.
Materials and methods

Detailed methods are described in Supplementary materials and methods (see Supplementary material).
Animals
Female C57BL/6, FVB/NJ and GFP transgenic mice (C57BL/6 or FVB/NJ background) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and female Fisher 344 rats were purchased from Charles River Breeding Laboratories (Wilmington, MA, USA). GFP bone marrow chimera mice were prepared as before [15] . C57BL/6J-Tg[COL1α2-CreER(T)] mice, carrying a Cre-recombinase under control of a regulatory sequence from the α2(I) collagen gene, were a generous gift from Dr Benoit de Crombrugghe of the University of Texas MD Andersen Cancer Center [16] . WCB6F1/J Kitl Sl Kitl Sld mice were purchased from the Jackson Laboratory. All animal studies were reviewed and approved by the University Committee on Use and Care of Animals at the University of Michigan.
Induction of pulmonary fibrosis
Animals were intratracheally injected with bleomycin (Blenoxane; Mead Johnson, Princeton, NJ, USA) at a dose of 2.5 U/kg body weight for mice and 7.5 U/kg body weight for rats, as before [17] . The control group received the same volume of phosphate-buffered saline (PBS) only. Where indicated, SCF-treated mice received recombinant SCF (R&D systems, Minneapolis, MN, USA) intratracheally at a dose of 0.1 µg/g body weight.
Human lung fibroblasts
Human lung fibroblasts from IPF patients and control subjects were generously provided by Dr Antonio Xaubet (Universitat de Barcelona, Spain) and Dr Carol Feghali-Bostwick (University of Pittsburgh, PA, USA).
Cell migration assay
Assays were performed using a 24-well cell migration kit (Corning, Lowell, MA, USA), according to the instruction manual. Freshly isolated whole BM cells were incubated with Calcein-AM (BD Biosciences) for 30 min at 37
• C before assay. After 4 h at 37
• C, the migrated cells were collected for fluorescence measurements using a Gemini EM (Molecular Devices) plate reader.
Statistics
Differences between means of various treatments were assessed for statistical significance by ANOVA, followed by post hoc analysis using Scheffé's test for comparison between any two groups; p < 0.05 was considered significant.
Results
SCF expression was induced in BLM-induced pulmonary fibrosis
The rodent pulmonary fibrosis model was induced as before [17] and at the indicated time points bronchoalveolar lavage fluid (BALF), plasma and lung tissue samples were collected for analysis of SCF expression. The results showed that SCF protein was undetectable in BALF from control mice, as determined by ELISA, but was highly induced in samples from BLM-treated mice at all the indicated time points ( Figure 1A ). Similar assay of serum samples indicated significantly elevated levels of SCF in BLM-treated animals relative to controls ( Figure 1B ). These determinations detected only soluble SCF; however, for the lung tissue samples both soluble and membrane-bound forms were analysed by western blotting. In control and BLM-treated lung samples both membrane-bound and soluble forms were detectable ( Figure 1C ). The membrane-bound product contains a proteolytic cleavage site encoded by exon 6 and post-translational processing at this site results in the soluble form. While membrane-bound SCF was slightly reduced in BLMtreated lung samples, the soluble form was increased relative to the control samples at all time points, with the highest increase at days 3-7 ( Figure 1C ). However, these differences in lung SCF protein levels in response to BLM treatment were not reflected in SCF mRNA levels, which were not significantly different between the BLM-treated versus control samples (data not shown), suggesting that the increase in lung soluble SCF was predominantly due to post-translational processing. To determine the cellular source of lung SCF expression, whole-lung, single-cell suspensions from BLMtreated mice were sorted to purify cells on the basis of CD3 (T-cells) or CD11b (inflammatory cells) expression, or absence of both markers (CD3 -/CD11b -). When the sorted cells were analysed for SCF mRNA by real-time PCR, expression was essentially limited to the double-negative cells, which was over 100-fold higher than in CD3-or CD11b-positive cells ( Figure 1D ). These findings suggested that primarily structural cells, instead of inflammatory/immune cells, were the main cellular source of SCF in BLM-induced pulmonary fibrosis. Fibroblasts are known to express SCF [13, 14] . The ELISA results showed that soluble SCF was significantly increased in conditioned media of lung fibroblasts from day 7 and day 14 BLM-treated animals, relative to those from their respective control animals ( Figure 1E ), suggesting that lung fibroblasts were an important source of SCF in the BLM model.
SCF-induced migration of c-Kit
+ BM cells to the lung Figure 2A ). These mutant mice are compound heterozygotes of a null SCF mutation (Sl) and the Steel-Dickie (Sld) mutation, which lacks membrane-bound SCF and exhibit reduced serum levels of soluble SCF [12] (see Supplementary material, Figure S1 ). Figure 2B ). This pattern of changes in the percentage of c-Kit + cells in the two compartments would be consistent with induced migration of these cells from the BM to the lung as a result of treatment with either BLM or SCF. We further evaluated this possibility by using GFP BM chimeric mice. After stable engraftment the mice were treated with saline or BLM, and 7 days later the lung cells were analysed for GFP and c-Kit expression by flow cytometry. The results confirmed that the increased portion of c-Kit + cells in the injured lung was derived from BM on the basis of GFP expression ( Figure 2C ).
An in vitro assay using modified Boyden chambers was undertaken to see whether SCF was chemotactic for bone marrow cells. As shown in Figure 3 , SCF exerted a robust effect on migration of freshly isolated rat BM cells. This effect was abolished by suppression of c-Kit expression, using c-Kit siRNA ( Figure E2 ) or c-Kit kinase inhibitor, imatinib. Interestingly, lung tissue extracts from control animals did not affect BM cell migration, whereas extracts from the BLM group mimicked the effect of SCF, which was also suppressed by c-Kit siRNA pretreatment, suggesting the effect in a SCF-dependent manner. These findings confirmed the ability of pure SCF and SCF in lung extracts of BLMtreated animals to directly increase the c-Kit-dependent migratory activity of BM cells. 
Increased c-Kit
+ collagen I + cells in the lung SCF is reported to recruit c-Kit + collagen I + BMderived cells [14] . We performed immunostaining for c-Kit and Cre on lung sections of BLM-treated Col-Cre mice, which carry a Cre-recombinase under the control of a regulatory sequence from the α2(I) collagen gene [16] . Co-localization of c-Kit and Cre showed the presence of c-Kit + collagen I + cells in the injured lung ( Figure 5A we could detect the presence of c-Kit + collagen I + cells in lung fibroblast cultures ( Figure 5A , lower panel, and C) and the percentage of these cells was significantly higher in cultures from BLM-treated versus SAL-treated lungs (2.69% versus 0.96%, respectively; p < 0.05, n = 5).
Expression of c-Kit in lung fibroblast cultures was evaluated. Cultures from BLM-treated or control animals revealed detectable expression of c-Kit by real time PCR ( Figure 6A ). Treatment with SCF caused a significantly higher level (3.2-fold versus 1.5-fold) in c-Kit mRNA in cells from BLM-treated animals when compared to the response in cells from controls. Moreover, higher induction of c-Kit expression by SCF was noted in lung fibroblast cultures isolated from IPF patients compared to cells from control subjects ( Figure 6B ), suggesting that this might be a property of fibroblast cultures from fibrotic lungs. The expressed cKit was functionally active, since SCF treatment caused rapid phosphorylation of this receptor, peaking at about 5 min and sustained for at least 10 min ( Figure 6C) . Notably, when compared to the predominantly c-Kit 
population, this c-Kit
+ subpopulation was essentially αSMA negative and expressed lower levels of collagen I but significantly higher levels of TGFβ ( Figure 7A , B). This would be consistent with a paracrine role for these BM-derived c-Kit + collagen I + cells, as suggested above.
SCF deficiency attenuated BLM-induced lung fibrosis
The importance of this pathway in BLM-induced lung fibrosis was evaluated in mice made deficient in SCF by intratracheal treatment with anti-SCF antibodies or by use of Kitl Sl /Kitl Sl-d mutant mice. When subjected to BLM-induced lung injury, the antibodytreated groups at doses of antibody ≥150 µg/animal and Kitl Sl /Kitl Sl-d mutant mice showed significantly reduced fibrosis, both morphologically [haematoxylin and eosin (H&E) or Masson's trichrome stain] and biochemically by hydroxyproline analysis (see Supplementary material, Figures S3A, B, S8A , B, respectively). Notably, the reduction in fibrosis by anti-SCF antibody treatment was accompanied with a significant reduction in BLM-induced increase in BM-derived cells in the lung (see Supplementary material, Figure  S3C ). These data, taken together, indicated an essential role for the SCF-c-Kit signalling pathway in BLMinduced pulmonary fibrosis.
Discussion
Recent studies suggest that organ injury is 'sensed' distally in the bone marrow by cells that can migrate to the site of damage and undergo differentiation to aid in repair or promotion of fibrosis [18] . However, the nature of the signal(s) from the injured distal organ and the mechanism of sensing, as well as recruitment from the bone marrow, have not been fully elucidated in the case of pulmonary fibrosis. Induced lung SCF expression plays an essential role in airway remodelling in an allergic airway disease model [14] . In addition, alveolar fibroblasts from IPF patients secrete more SCF [13] . Thus, ample evidence is available to suggest the potential importance of the SCF-c-Kit pathway in pulmonary fibrosis. In this study the significance of the SCF-c-Kit signal pathway was investigated with respect to recruitment of BM-derived cells in the context of BLM-induced lung injury and fibrosis.
The findings revealed a coincident increase in expression of SCF at the site of lung injury and in the level of circulating SCF as early as day 3 after bleomycin treatment. This is comparable to observations in brain injury, myocardial infarction, serum nephrotoxic nephritis and wire-induced vascular injury, wherein SCF expression is also increased during injury and repair [8] [9] [10] 12] . It is noteworthy that increased soluble SCF was mainly regulated at the level of post-translational processing, consistent with results reported on the role of SCF in the remodelling process associated with nephrotoxic nephritis [8] . BLM-induced responses are known to include induction of some proteinases, such as MMP-2 and MMP-9 [19] , which has the capacity to mediate cleavage of membrane-bound SCF with release into the interstitium and blood circulation as a soluble mediator, as observed in the BM niche [20] and vascular injury [12] .
Current concepts of tissue repair and fibrotic process implicate the recruitment of BM-derived fibroblast-like cells to sites of injury in response to chemokine signals released from the injured tissue [21] . Here our evidence suggested that BLM-induced release of soluble SCF from the structural cells of the lung resulted in elevated levels of circulating SCF in plasma, which played a significant role in the recruitment of c-Kit + cells from BM to the injured lung. The concomitantly decreased c-Kit + cells in the BM suggested that normal homing of circulating progenitor cells is disrupted. C-Kit, considered as a marker for BM-derived haematopoietic stem cells, is also expressed on mast cells and dendritic cells [22] [23] [24] . However, mast cell participation was limited or negligible in our BLM-induced pulmonary fibrosis model, according to expression of the mast cell marker, tryptase (data not shown). The role of dendritic cells remains to be specifically elucidated. We showed here that BM-derived c-Kit + cells are capable of elaborating factors to promote myofibroblast differentiation and thus play a paracrine pro-fibrotic role. Some of these cells appear to be the c-Kit + collagen I + cells that were isolated along with lung fibroblasts, whose numbers were increased when isolated from fibrotic lungs. While they expressed type I collagen, these BMderived cells, unlike lung fibroblasts, cannot undergo myofibroblast differentiation, as previously shown [14, 25] . In contrast, fibrocytes are not known to express c-Kit but can undergo myofibroblast differentiation and thus are capable of contributing to matrix deposition directly [26] . While exogenous BM-derived mesenchymal stem cells (MSCs) protect against lung injury [27, 28] , endogenous recruitment of BM-derived cells, such as fibrocytes, mediated by the SDF-1/CXCR4 axis is reported to promote pulmonary fibrosis [26, 29, 30] . BM cell trafficking by SDF-1-CXCR4 is modulated by c-Kit and its phosphorylation [31] . This crosstalk between the SDF-1-CXCR4 and SCF-c-Kit signalling pathways favours the profibrotic role of the recruited endogenous BM c-Kit + cells, as observed previously for fibrocytes [26, 29, 30] . In this study, expression of c-Kit on some cells in cultured fibroblasts was significantly greater and more responsive to SCF induction in cells from fibrotic lungs, including those from IPF patients, which has been previously reported [32] . This would be consistent with the paracrine role of these c-Kit + cells in promoting the elevated myofibroblast differentiation in fibroblasts isolated from fibrotic lung tissue. Moreover, recruitment of haematopoietic stem cells and endothelial progenitor cells via activation of the SCF-c-Kit signalling pathway is shown to be essential for osteogenesis [11] , a remodelling process akin to fibrosis, wherein the key participating cell type, the osteoblast, is viewed as the counterpart of a fibroblast [33] . In this regard, the role of SCF-c-Kit in osteogenesis is highly reminiscent of that in pulmonary fibrosis in the BLM model.
Direct in vivo confirmation of the role of SCF-c-Kit in pulmonary fibrosis was provided by animal models. Imatinib was found to have anti-fibrotic activity in the BLM-induced lung fibrosis model [34, 35] . Although imatinib is a tyrosine kinase inhibitor capable of suppressing the effect of SCF, it is not specific for c-Kit. To attain greater specificity, anti-SCF antibodies as well as SCF deficiency in Kitl Sl /Kitl Sl-d mutant mice were used, and both strategies resulted in significant attenuation of BLM-induced pulmonary fibrosis. Taken together, the findings directly implicate the SCF-c-Kit axis in the pathogenesis of BLM-induced lung fibrosis, with activation of the SCF-c-Kit pathway resulting in the recruitment of cells from the BM compartment to sites of lung injury, with consequent paracrine activation of fibroblasts. Elevated c-Kit expression in IPF lung fibroblast cultures suggests potential relevance to human pulmonary fibrosis. Thus, attenuation of SCF expression and function may be an effective therapeutic modality for treatment of pulmonary fibrosis.
